Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Recruiting now

Conditions studied: Rare Diseases, Generalized Myasthenia Gravis (gMG)

In brief

This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.

Key facts

Study ID

NCT07247279

Run by

AstraZeneca

People needed

450

Starts

2025-12-23

Expected to finish

2029-12-31

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years) diagnosed with generalized MG positive for acetylcholine receptor (AChR) antibodies.
• Provision of signed and dated written informed consent.

You may not qualify if…

• Participants currently enrolled in clinical studies for treatment of gMG.
• Ocular MG only.

Where it is running

• Research Site — Kazan', Russia (enrolling)
• Research Site — Moscow, Russia (enrolling)
• Research Site — Novosibirsk, Russia (enrolling)
• Research Site — Rostov-on-Don, Russia (enrolling)
• Research Site — Saint Petersburg, Russia (enrolling)
• Research Site — Samara, Russia (enrolling)
• Research Site — Ufa, Russia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.